Research programme: cedar pollen allergy immunotherapy - REGiMMUNE

Drug Profile

Research programme: cedar pollen allergy immunotherapy - REGiMMUNE

Alternative Names: RGI-1001

Latest Information Update: 06 Mar 2014

Price : $50

At a glance

  • Originator REGiMMUNE
  • Class Antigens
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Allergic rhinitis

Most Recent Events

  • 28 Feb 2014 REGiMMUNE's cedar pollen allergy immunotherapy programme is available for licensing in World (excluding Japan) as of 28 Feb 2014.
  • 18 Jul 2011 Preclinical development is ongoing in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top